“Teriparatide reduces fracture risk in defined osteoporosis populations.”

01 · Answer

Supported with scope

The pivotal evidence and label support vertebral and nonvertebral fracture-risk reduction in studied high-risk populations.

What kind of evidence this is

Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.

What this answer covers

Labeled osteoporosis populations at high fracture risk. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.

Question type

Clinical outcomes. What a study measured about people's health, symptoms, or ability to function.